Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763199 · ClinicalTrials.gov registry record · Phase 2
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
A Phase 2 study of Fallopian Tube Carcinoma and Peritoneal Carcinoma, sponsored by University of California, Davis.
- Active
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05763199 is a Phase 2 study of Fallopian Tube Carcinoma and Peritoneal Carcinoma that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 20 participants, below the 352-participant average among 13 other Fallopian Tube Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05763199, a Phase 2 study of Fallopian Tube Carcinoma and Peritoneal Carcinoma, is active but no longer recruiting, sponsored by University of California, Davis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Chemotherapy
- DIETARY_SUPPLEMENT AHCC
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763199
The ClinicalTrials.gov registry entry for NCT05763199 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 352-participant average among 13 other Fallopian Tube Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05763199 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05763199 about?
NCT05763199 is a clinical study titled "Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy". This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.
What is the current status of trial NCT05763199?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-08-01. Estimated completion is 2027-03-01.
What conditions does trial NCT05763199 study?
This clinical trial studies the following conditions: Fallopian Tube Carcinoma, Peritoneal Carcinoma, Ovarian Epithelial Carcinoma.
What interventions are being tested in trial NCT05763199?
The interventions under investigation include: Placebo (OTHER), Chemotherapy (DRUG), AHCC (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05763199?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05763199 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.